Journal of Vaccines & Vaccination

Evaluating a Bivalent COVID-19 Vaccine's Immunogenicity and Protection in Mice

Chan Wong^* Department of Clinical Microbiology, National Institute of Respiratory Diseases (INER), Mexico City, Mexico
^*Correspondence: Chan Wong, Department of Clinical Microbiology, National Institute of Respiratory Diseases (INER), Mexico City, Mexico, Email:

Received: 05-Jul-2023, Manuscript No. JVV-23-22125; Editor assigned: 07-Jul-2023, Pre QC No. JVV-23-22125 (PQ); Reviewed: 21-Jul-2023, QC No. JVV-23-22125; Revised: 28-Jul-2023, Manuscript No. JVV-23-22125 (R); Published: 07-Aug-2023, DOI: 10.35248/2157-7560.23.S22.003

About the Study

The ongoing COVID-19 pandemic has prompted an urgent global effort to develop safe and effective vaccines. One potential approach involves the use of recombinant vaccines, which utilize genetic engineering techniques to produce viral antigens. This study examines the immunogenicity and protective effects of a recombinant bivalent COVID-19 vaccine in mice, shedding light on the potential of this vaccine candidate in combating the SARS-CoV-2 virus.

Recombinant vaccines utilize recombinant DNA technology to produce viral antigens, such as spike proteins, that can stimulate an immune response. In the case of COVID-19, the spike protein is a key target as it plays a crucial role in viral entry into human cells. Recombinant vaccines offer several advantages, including the ability to produce large quantities of antigens, flexibility in antigen selection, and potential for rapid scalability [1-3].

Immunogenicity of the bivalent COVID-19 vaccine

The bivalent COVID-19 vaccine under investigation combines two different recombinant spike proteins derived from distinct SARS-CoV-2 variants. This approach aims to broaden the immune response and enhance protection against multiple strains of the virus [4-6]. In a study conducted in mice, the vaccine's immunogenicity was evaluated by measuring the levels of neutralizing antibodies and T-cell responses.

The results demonstrated that the recombinant bivalent vaccine elicited robust immune responses in mice. High levels of neutralizing antibodies were detected, indicating the potential to effectively block viral entry. Additionally, T-cell responses, which are crucial for long-term immunity, were observed. The vaccine successfully induced both CD4⁺ T-helper cell responses and CD8⁺ cytotoxic T-cell responses, suggesting the activation of a comprehensive immune defense against the virus [7].

Protective effects in mouse models

To assess the protective effects of the vaccine, mice were subsequently challenged with live SARS-CoV-2 virus. Encouragingly, the vaccinated mice showed reduced viral loads compared to the control group, indicating that the vaccine was capable of limiting viral replication [8]. Furthermore, vaccinated mice exhibited milder clinical symptoms and lower lung inflammation, demonstrating a potential for the vaccine to mitigate disease severity.

These findings suggest that the recombinant bivalent COVID-19 vaccine induces a robust immune response in mice, providing a basis for further evaluation and potential translation to human trials. However, it is essential to interpret these results with caution, as the immune response and disease course in mice may not precisely mirror those in humans. Human clinical trials are necessary to validate the vaccine's efficacy and safety profile in real-world scenarios.

Considerations for translation to human trials

As the development of vaccines progresses, it is crucial to consider several factors when translating findings from animal studies to human trials. First, the vaccine's safety profile must be rigorously assessed; ensuring that it does not cause adverse effects or exacerbate any underlying conditions [9]. Animal studies provide initial insights, but human trials offer a more comprehensive evaluation of vaccine safety.

Second, the vaccine's effectiveness against emerging SARS-CoV-2 variants should be carefully investigated. The bivalent vaccine, with its inclusion of multiple spike proteins, may provide broader protection against viral variants. However, ongoing surveillance and monitoring of viral evolution are crucial to inform vaccine design and ensure continuous efficacy against new strains [10].

Third, the logistics of large-scale vaccine production, distribution, and administration should be considered. Recombinant vaccines offer advantages in terms of scalability and manufacturing, but logistical challenges must be addressed to ensure equitable access to the vaccine worldwide.

Conclusion

The investigation of a recombinant bivalent COVID-19 vaccine in mouse models has provided promising results regarding immunogenicity and protective effects. The vaccine induced robust immune responses, including the production of neutralizing antibodies and activation of T-cell responses. Furthermore, the vaccine demonstrated potential in reducing viral loads and mitigating disease severity in mice.

These findings pave the way for further exploration and translation to human clinical trials. However, it is crucial to conduct rigorous safety evaluations, assess efficacy against emerging viral variants, and address logistical challenges associated with large-scale production and distribution. With continued research and collaboration, recombinant vaccines may contribute significantly to the global effort to control and combat the COVID-19 pandemic.

References

1. Fathi M, Taghizadeh F, Mojtahedi H, Zargar Balaye, Jame S, Markazi Moghaddam N. The effects of Alzheimer’s and Parkinson’s disease on 28-day mortality of COVID-19. Revue Neurologique. 2022;178(1-2):129-136.

   [Crossref] [Google Scholar] [PubMed]

2. Boura I, Chaudhuri KR. Coronavirus disease 2019 and related Parkinsonism: The clinical evidence thus far. Mov Disord Clin Pract. 2022;9(5):584-593.

   [Crossref] [Google Scholar] [PubMed]

3. Marand AJB, Bach C, Janssen D, Heesakkers J, Ghojazadeh M, Vogeli TA, et al. Lower urinary tract signs and symptoms in patients with COVID-19. BMC Infect Dis. 2021;21(1):1-5.

   [Crossref] [Google Scholar] [PubMed]

4. Ebner B, Volz Y, Mumm JN, Stief CG, Magistro G. The COVID-19 pandemic-what have urologists learned?. Nat Rev Urol. 2022;19(6):344-356.

   [Google Scholar] [PubMed]

5. Edalatifard M, Akhtari M, Salehi M, Naderi Z, Jamshidi A, Mostafaei S, et al. Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial. Eur Respir J. 2020;56(6):2002808.

   [Crossref] [Google Scholar] [PubMed]

6. Zaitsev AA, Golukhova EZ, Mamalyga ML, Chernov SA, Rybka MM, Kryukov EV, et al. Efficacy of methylprednisolone pulse therapy in patients with COVID-19. Clin Microbiol Antimicrob Chemothe. 22(2):88-91.

   [Crossref] [Google Scholar]

7. Gonzaga L, de Assis Barros D’ F, Zanella E, Kalliiope De Sa Paraskevopoulos D, de Lima Galvao L, Yamaguti A, et al. Methylprednisolone pulse therapy in COVID-19 as the first choice for public health: When right timing breaks controversies-emergency guide. Open Access Emerg Med 2021;9:84-114.

   [Crossref] [Google Scholar]

8. Bodro M, Compta Y, Sanchez-Valle R. Presentations and mechanisms of CNS disorders related to COVID-19. Neurol Neuroimmunol Neuroinflamm. 2020;11:8(1):e923.

   [Crossref] [Google Scholar] [PubMed]

9. Edalatifard M, Akhtari M, Salehi M, Naderi Z, Jamshidi A, Mostafaei S, et al. Intravenous methylprednisolone pulse as a treatment for hospitalized severe COVID-19 patients: Results from a randomized controlled clinical trial. Eur Respir J. 2020;56(6):2002808.

   [Crossref] [Google Scholar] [PubMed]

10. Zanella LD, Paraskevopoulos DD, Galvao LD, Yamaguti A. Methylprednisolone pulse therapy in COVID-19 as the first choice for public health: When right timing breaks controversies-emergency guide. Open Access Emerg Med. 2021;9(3):84-114.

    [Crossref] [Google Scholar]